Paper Information

Journal:   IRANIAN JOURNAL OF MEDICAL HYPOTHESES AND IDEAS   2008 , Volume 2 , Number 2; Page(s) 0 To 0.
 
Paper: 

THERAPEUTIC POTENTIAL OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (ANTI-VEGF) AGENTS IN ORBITAL LYMPHANGIOMA

 
 
Author(s):  ATARZADEH A., NOUROUZZADEH M.H., SHARIFI MOHAMMAD*
 
* DEPARTMENT OF OPHTHALMOLOGY, POOSTCHI OPHTHALMOLOGY RESEARCH CENTER, SHIRAZ UNIVERSITY OF MEDICAL SCIENCES, SHIRAZ, IRAN
 
Abstract: 

Orbital lymphangiomas are non encapsulated tumors and one of the most common vascular tumors in children. Surgery indicated for selected patients but complete resection of tumors is difficult due to their diffuse infiltration within adjacent tissues. Carbon dioxide, contact Nd:YAG lasers and percutaneous sclerotherapy as an alternative to surgical resection have variable success. Challenge continues to be to find a safe and effective therapeutic modality for this purpose. There are many data supporting a casual role for vascular endothelial growth factor (VEGF) in lymphangiogenesis. One possible strategy for treating orbital lymphangioma is to inhibit VEGF activity by competitively binding VEGF with a specific neutralizing anti-VEGF antibody. The vitreo-retinal service in the recent years enjoyed a high level of success in managing diabetic retinopathy, choroidal neovascularization, and neovascular glaucoma using anti-VEGF strategies. Efficacy and tolerability have been demonstrated for drugs targeting VEGF. We herein hypothesize that intralesional application of anti-VEGF agents such as pegaptanib, ranibizumab and bevacizumab are potentially useful for treating orbital lymphangioma and preventing its complications. Further investigations are needed to place this mode of treatment alongside orbital lymphangioma therapeutics.

 
Keyword(s): ORBITAL LYMPHANGIOMA, ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR, IINTRALESIONAL, TREATMENT
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 83
 
Latest on Blog
Enter SID Blog